Predominant expression of mutant EGFR (EGFRvIII) is rare in primary glioblastomas - PubMed (original) (raw)
Predominant expression of mutant EGFR (EGFRvIII) is rare in primary glioblastomas
Wojciech Biernat et al. Brain Pathol. 2004 Apr.
Abstract
EGFR amplification is a frequent genetic alteration in primary (de novo) glioblastomas, and is often associated with structural alterations. Most common is variant III (EGFRvIII), which results from a non-random 801 bp in-frame deletion of exons 2 to 7 of the EGFR gene. We assessed amplification and overexpression of EGFRvIII and wild-type EGFR in 30 glioblastoma biopsies. Immunohistochemically, EGFR overexpression was observed in 20 (67%) of 30 glioblastomas. Eight (27%) cases also showed immunoreactivity to an EGFRvIII antibody. In 6 of these cases, the pattern of EGFR and EGFRvIII overexpression was compared in serial sections: In 4 cases, areas with immunoreactivity to EGFRvIII largely coincided with wild-type EGFR expression. In the other 2 cases, the areas immunoreactive to EGFRvIII were significantly less extensive than EGFR-positive areas. To assess whether EGFRvIII is predominantly amplified in tumors with concurrent wild-type EGFR amplification, we carried our real-time quantitative PCR using 2 sets of primers located in exon 2 and intron 15 of the EGFR gene. A > 5-fold ratio of relative copy numbers between intron 15 (present both in wild-type EGFR and EGFRvIII) and exon 2 (present only in wild-type EGFR, but missing in EGFRvIII) suggested predominant amplification of EGFRvIII in only 3 (10%) of 30 glioblastomas. The observation that intratumoral wild-type EGFR overexpression is often more extensive and that predominant amplification of EGFRvIII is a rare event would limit the effectiveness of therapeutic approaches based on selective targeting of EGFRvIII.
Similar articles
- Simultaneous detection of EGFR amplification and EGFRvIII variant using digital PCR-based method in glioblastoma.
Fontanilles M, Marguet F, Ruminy P, Basset C, Noel A, Beaussire L, Viennot M, Viailly PJ, Cassinari K, Chambon P, Richard D, Alexandru C, Tennevet I, Langlois O, Di Fiore F, Laquerrière A, Clatot F, Sarafan-Vasseur N. Fontanilles M, et al. Acta Neuropathol Commun. 2020 Apr 17;8(1):52. doi: 10.1186/s40478-020-00917-6. Acta Neuropathol Commun. 2020. PMID: 32303258 Free PMC article. Clinical Trial. - Epidermal Growth Factor Receptor Variant III (EGFRvIII) Positivity in _EGFR_-Amplified Glioblastomas: Prognostic Role and Comparison between Primary and Recurrent Tumors.
Felsberg J, Hentschel B, Kaulich K, Gramatzki D, Zacher A, Malzkorn B, Kamp M, Sabel M, Simon M, Westphal M, Schackert G, Tonn JC, Pietsch T, von Deimling A, Loeffler M, Reifenberger G, Weller M; German Glioma Network. Felsberg J, et al. Clin Cancer Res. 2017 Nov 15;23(22):6846-6855. doi: 10.1158/1078-0432.CCR-17-0890. Epub 2017 Aug 29. Clin Cancer Res. 2017. PMID: 28855349 - Genetic Alterations of Epidermal Growth Factor Receptor in Glioblastoma: The Usefulness of Immunohistochemistry.
Lee M, Kang SY, Suh YL. Lee M, et al. Appl Immunohistochem Mol Morphol. 2019 Sep;27(8):589-598. doi: 10.1097/PAI.0000000000000669. Appl Immunohistochem Mol Morphol. 2019. PMID: 29912767 - Detection of wild-type EGFR amplification and EGFRvIII mutation in CSF-derived extracellular vesicles of glioblastoma patients.
Figueroa JM, Skog J, Akers J, Li H, Komotar R, Jensen R, Ringel F, Yang I, Kalkanis S, Thompson R, LoGuidice L, Berghoff E, Parsa A, Liau L, Curry W, Cahill D, Bettegowda C, Lang FF, Chiocca EA, Henson J, Kim R, Breakefield X, Chen C, Messer K, Hochberg F, Carter BS. Figueroa JM, et al. Neuro Oncol. 2017 Oct 19;19(11):1494-1502. doi: 10.1093/neuonc/nox085. Neuro Oncol. 2017. PMID: 28453784 Free PMC article. - Epidermal growth factor receptor in glioma: signal transduction, neuropathology, imaging, and radioresistance.
Hatanpaa KJ, Burma S, Zhao D, Habib AA. Hatanpaa KJ, et al. Neoplasia. 2010 Sep;12(9):675-84. doi: 10.1593/neo.10688. Neoplasia. 2010. PMID: 20824044 Free PMC article. Review.
Cited by
- An Overview of EGFR Mechanisms and Their Implications in Targeted Therapies for Glioblastoma.
Rodriguez SMB, Kamel A, Ciubotaru GV, Onose G, Sevastre AS, Sfredel V, Danoiu S, Dricu A, Tataranu LG. Rodriguez SMB, et al. Int J Mol Sci. 2023 Jul 5;24(13):11110. doi: 10.3390/ijms241311110. Int J Mol Sci. 2023. PMID: 37446288 Free PMC article. Review. - CAR-NK cell therapy for glioblastoma: what to do next?
Xiong Q, Zhu J, Zhang Y, Deng H. Xiong Q, et al. Front Oncol. 2023 Jun 19;13:1192128. doi: 10.3389/fonc.2023.1192128. eCollection 2023. Front Oncol. 2023. PMID: 37404752 Free PMC article. Review. - Understanding the molecular profiling of diffuse gliomas classification: A brief overview.
Rubiano EGO, Baldoncini M, Cómbita AL, Payán-Gómez C, Gómez-Amarillo DF, Hakim F, Figueredo LF, Forlizzi V, Rangel CC, Luzzi S, Campero A, Parra-Medina R. Rubiano EGO, et al. Surg Neurol Int. 2023 Jun 30;14:225. doi: 10.25259/SNI_209_2023. eCollection 2023. Surg Neurol Int. 2023. PMID: 37404501 Free PMC article. - Anoctamins and Calcium Signalling: An Obstacle to EGFR Targeted Therapy in Glioblastoma?
Dewdney B, Ursich L, Fletcher EV, Johns TG. Dewdney B, et al. Cancers (Basel). 2022 Nov 30;14(23):5932. doi: 10.3390/cancers14235932. Cancers (Basel). 2022. PMID: 36497413 Free PMC article. Review. - The IAP antagonist birinapant enhances chimeric antigen receptor T cell therapy for glioblastoma by overcoming antigen heterogeneity.
Song EZ, Wang X, Philipson BI, Zhang Q, Thokala R, Zhang L, Assenmacher CA, Binder ZA, Ming GL, O'Rourke DM, Song H, Milone MC. Song EZ, et al. Mol Ther Oncolytics. 2022 Nov 15;27:288-304. doi: 10.1016/j.omto.2022.11.004. eCollection 2022 Dec 15. Mol Ther Oncolytics. 2022. PMID: 36458202 Free PMC article.
References
- Archer GE, Sampson JH, Lorimer IA, McLendon RE, Kuan CT, Friedman AH, Friedman HS, Pastan IH, Bigner DD (1999) Regional treatment of epidermal growth factor receptor vIII‐expressing neoplastic meningitis with a single‐chain immunotoxin, MR‐1. Clin Cancer Res 5:2646–2652. - PubMed
- Cavenee WK (2002) Genetics and new approaches to cancer therapy. Carcinogenesis 23: 683–686. - PubMed
- Ciardiello F, Tortora G (2001) A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor. Clin Cancer Res 7: 2958–2970. - PubMed
- Diedrich U, Lucius J, Baron E, Behnke J, Pabst B, Zoll B (1995) Distribution of epidermal growth factor receptor gene amplification in brain tumours and correlation to prognosis. J Neurol 242:683–688. - PubMed
- Ding H, Shannon P, Lau N, Wu X, Roncari L, Baldwin RL, Takebayashi H, Nagy A, Gutmann DH, Guha A (2003) Oligodendrogliomas result from the expression of an activated mutant epidermal growth factor receptor in a RAS transgenic mouse astrocytoma model. Cancer Res 63: 1106–1113. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous